肺部微生物组与肺癌发生、发展和治疗的关系研究进展

doi:10.19871/j.cnki.xfcrbzz.2024.05.016

摘要/Abstract

摘要： 肺部曾经被认为是无菌的,如今被证实存在一定的微生物定植,并且这些微生物在呼吸系统疾病的发病机制及治疗方面发挥着重要作用。肺癌作为世界第一大癌症,是由机体和环境因素之间相互作用引起的复杂疾病,在于大多数患者被诊断时已为晚期,病死率高。越来越多的证据表明,不同的肺部微生物组特征能够用于早期识别肺癌,并且对肺癌的发生、发展和治疗有一定的指导作用。本综述概括总结了肺部微生物与肺癌的关系、肺癌患者的肺部微生物特征、微生物在肺癌治疗中的应用前景等,以期为肺部微生物组作为新兴的生物标志物可对肺癌的诊治提供新思路,同时为今后肺癌微生物组的研究方向提出展望。

关键词: 肺部, 微生物组, 肺癌, 相关性

Abstract: The lung was once thought to be sterile, but it is now confirmed to have a certain colonization of microorganisms, playing an important role in the pathogenesis and treatment of respiratory system diseases. Lung cancer, as the world's leading cancer, is a complex disease caused by the interaction of host and environmental factors. Its terrifying aspect is that most patients are diagnosed at a late stage,with a high mortality rate. Increasing evidence suggests that different characteristics of the lung microbiota can identify lung cancer early and have a certain guiding role in the occurrence, development, and treatment of lung cancer. In this review, we summarize the relationship between lung microbiota and lung cancer,characteristic of pulmonary microorganisms in patients with lung cancer,application prospect of microorganisms in the treatment of lung cancer.We hope that the lung microbiota, as an emerging biological marker, can provide new ideas for the diagnosis and treatment of lung cancer, and also propose prospects for future research directions on the lung cancer microbiota.

Key words: Lung, Microbiome, Lung cancer, Relativity

中图分类号:

R563.9

孙小琴, 刘钰, 申席文, 虎维东. 肺部微生物组与肺癌发生、发展和治疗的关系研究进展[J]. 新发传染病电子杂志, 2024, 9(5): 83-88.

Sun Xiaoqin, Liu Yu, Shen Xiwen, Hu Weidong. Progress in the relationship between the lung microbiome and the occurrence, development and treatment of lung cancer[J]. Electronic Journal of Emerging Infectious Diseases, 2024, 9(5): 83-88.

参考文献

[1] 王庆忠, 范云, 沈祁烨. 人类微生物组学与健康及其临床检验的需求[J]. 分子诊断与治疗杂志, 2018, 10(1):67-72.
[2] NATALINI JG, SINGH S, SEGAL LN.The dynamic lung microbiome in health and disease[J]. Nat Rev Microbiol, 2023, 21(4):222-235.
[3] HAN B, ZHENG R, ZENG H, et al.Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53.
[4] GOTO T.Microbiota and lung cancer[J]. Semin Cancer Biol, 2022, 86(Pt 3):1-10.
[5] KING A. Exploring the lung microbiome's role in disease[J]. Nature, 2024, Online ahead of print.
[6] CHARLSON ES, BITTINGER K, HAAS AR, et al.Topographical continuity of bacterial populations in the healthy human respiratory tract[J]. Am J Respir Crit Care Med, 2011, 184(8):957-963.
[7] HILTY M, BURKE C, PEDRO H, et al.Disordered microbial communities in asthmatic airways[J]. PloS one, 2010, 5(1):e8578.
[8] DICKSON RP, ERB-DOWNWARD JR, MARTINEZ FJ, et al.The Microbiome and the Respiratory Tract[J]. Annu Rev Physiol, 2016, 78:481-504.
[9] SHAH BK, SINGH B, WANG Y, et al.Mucus Hypersecretion in Chronic Obstructive Pulmonary Disease and Its Treatment[J]. Mediators Inflamm, 2023, 2023:8840594.
[10] WYPYCH TP, WICKRAMASINGHE LC, MARSLAND BJ.The influence of the microbiome on respiratory health[J]. Nat Immunol, 2019, 20(10):1279-1290.
[11] HUANG J, HUANG J.Microbial Biomarkers for Lung Cancer:Current Understandings and Limitations[J]. J Clin Med, 2022, 11(24):7298.
[12] DICKSON RP, ERB-DOWNWARD JR, HUFFNAGLE GB.Towards an ecology of the lung:new conceptual models of pulmonary microbiology and pneumonia pathogenesis[J]. Lancet Respir Med, 2014, 2(3):238-246.
[13] DICKSON RP, MARTINEZ FJ, HUFFNAGLE GB.The role of the microbiome in exacerbations of chronic lung diseases[J]. Lancet, 2014, 384(9944):691-702.
[14] 陈丽霏, 张世倡, 肖林. 炎症性肠病中活性氧及抗氧化的研究进展[J]. 中国当代医药, 2020, 27(09):24-27.
[15] TSAY JJ, WU BG, SULAIMAN I, et al.Lower Airway Dysbiosis Affects Lung Cancer Progression[J]. Cancer Discov, 2021, 11(2):293-307.
[16] LU SSM, MOHAMMED Z, HäGGSTRöM C, et al. Antibiotics Use and Subsequent Risk of Colorectal Cancer:A Swedish Nationwide Population-Based Study[J]. J Natl Cancer Inst, 2022, 114(1):38-46.
[17] DANG AT, MARSLAND BJ.Microbes, metabolites, and the gut-lung axis[J]. Mucosal Immunol, 2019, 12(4):843-850.
[18] GEORGIOU K, MARINOV B, FAROOQI AA, et al.Gut Microbiota in Lung Cancer:Where Do We Stand?[J]. Int J Mol Sci, 2021, 22(19):10429.
[19] GE Y, WANG X, GUO Y, et al.Gut microbiota influence tumor development and Alter interactions with the human immune system[J]. J Exp Clin Cancer Res, 2021, 40(1):42.
[20] ASHIQUE S, DE RUBIS G, SIROHI E, et al.Short Chain Fatty Acids:Fundamental mediators of the gut-lung axis and their involvement in pulmonary diseases[J]. Chem Biol Interact, 2022, 368:110231.
[21] STRICKER S, HAIN T, CHAO C M, et al.Respiratory and Intestinal Microbiota in Pediatric Lung Diseases-Current Evidence of the Gut-Lung Axis[J]. Int J Mol Sci, 2022, 23(12):6791.
[22] NEJMAN D, LIVYATAN I, FUKS G, et al.The human tumor microbiome is composed of tumor type-specific intracellular bacteria[J]. Science, 2020, 368(6494):973-980.
[23] HE Z, GHARAIBEH RZ, NEWSOME RC, et al.Campylobacter jejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin[J]. Gut, 2019, 68(2):289-300.
[24] FELLOWS R, DENIZOT J, STELLATO C, et al.Microbiota derived short chain fatty acids promote histone crotonylation in the colon through histone deacetylases[J]. Nat Commun, 2018, 9(1):105.
[25] LIU F, LI J, GUAN Y, et al.Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer[J]. Int J Biol Sci, 2019, 15(11):2381-2392.
[26] GOODWIN AC, DESTEFANO SHIELDS CE, WU S, et al.Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis[J]. Proc Natl Acad Sci USA, 2011, 108(37):15354-15359.
[27] GARRETT WS.Cancer and the microbiota[J]. Science, 2015, 348(6230):80-86.
[28] 任清林, 何文博, 岳佳瑞. 两样本孟德尔随机化分析肠道菌群与肺癌的因果关系[J]. 中国胸心血管外科临床杂志, 2023, 30(11):1618-1627.
[29] KEELY S, TALLEY NJ, HANSBRO PM.Pulmonary-intestinal cross-talk in mucosal inflammatory disease[J]. Mucosal Immunol, 2012, 5(1):7-18.
[30] SANMAMED MF, CARRANZA-RUA O, ALFARO C, et al.Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins[J]. Clin Cancer Res, 2014, 20(22):5697-5707.
[31] BIAGI E, NYLUND L, CANDELA M, et al.Through ageing, and beyond:gut microbiota and inflammatory status in seniors and centenarians[J]. PloS One, 2010, 5(5):e10667.
[32] ANAND S, MANDE SS.Diet, Microbiota and Gut-Lung Connection[J]. Front Microbiol, 2018, 9:2147.
[33] VIEIRA RS, CASTOLDI A, BASSO PJ, et al.Butyrate Attenuates Lung Inflammation by Negatively Modulating Th9 Cells[J]. Front Immunol, 2019, 10:67.
[34] LI L, FANG Z, LIU X, et al.Lactobacillus reuteri attenuated allergic inflammation induced by HDM in the mouse and modulated gut microbes[J]. PloS One, 2020, 15(4):e0231865.
[35] 葛怡俊, 曹超. 肺部微生态与肺癌的关系研究进展[J]. 新医学, 2023, 54(8):540-544.
[36] GREATHOUSE KL, WHITE JR, VARGAS AJ, et al.Interaction between the microbiome and TP53 in human lung cancer[J]. Genome Biol, 2018, 19(1):123.
[37] DE VISSER KE, JOYCE JA.The evolving tumor microenvironment:From cancer initiation to metastatic outgrowth[J]. Cancer Cell, 2023, 41(3):374-403.
[38] LIU HX, TAO LL, ZHANG J, et al.Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects[J]. Int J Cancer, 2018, 142(4):769-778.
[39] GALEANO NIÑO JL, WU H, LACOURSE KD, et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer[J]. Nature, 2022, 611(7937):810-817.
[40] FU Y, LI J, CAI W, et al.The emerging tumor microbe microenvironment:From delineation to multidisciplinary approach-based interventions[J]. Acta Pharm Sin B, 2024, 14(4):1560-1591.
[41] LI R, LI J, ZHOU X.Lung microbiome:new insights into the pathogenesis of respiratory diseases[J]. Signal Transduct Target Ther, 2024, 9(1):19.
[42] LEE SH, SUNG JY, YONG D, et al.Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions[J]. Lung Cancer, 2016, 102:89-95.
[43] LAROUMAGNE S, SALINAS-PINEDA A, HERMANT C, et al.Incidence and characteristics of bronchial colonisation in patient with lung cancer:a retrospective study of 388 cases[J]. Rev Mal Respir, 2011, 28(3):328-335.
[44] XIA X, CHEN J, CHENG Y, et al.Comparative analysis of the lung microbiota in patients with respiratory infections, tuberculosis, and lung cancer:A preliminary study[J]. Front Cell Infect Microbiol, 2022, 12:1024867.
[45] LIANG HY, LI XL, YU X S, et al.Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk:a systematic review[J]. Int J Cancer, 2009, 125(12):2936-2944.
[46] LIU NN, YI C X, WEI LQ, et al.The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells[J]. Cancer Cell, 2024, 42(2):318-322.
[47] NARUNSKY-HAZIZA L, SEPICH-POORE GD, LIVYATAN I, et al.Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions[J]. Cell, 2022, 185(20):3789-3806.
[48] AKHTAR N, BANSAL JG.Risk factors of Lung Cancer in nonsmoker[J]. Curr Probl Cancer, 2017, 41(5):328-339.
[49] ZHAI K, DING J, SHI HZ.HPV and lung cancer risk:a meta-analysis[J]. J Clin Virol, 2015, 63:84-90.
[50] CARPAGNANO GE, KOUTELOU A, NATALICCHIO MI, et al.HPV in exhaled breath condensate of lung cancer patients[J]. Br J Cancer, 2011, 105(8):1183-1190.
[51] CHENG YW, WU MF, WANG J, et al.Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation[J]. Cancer Res, 2007, 67(22):10686-10693.
[52] CHEN FF, YAN JJ, LAI WW, et al.Epstein-Barr virus-associated nonsmall cell lung carcinoma:undifferentiated "lymphoepithelioma-like" carcinoma as a distinct entity with better prognosis[J]. Cancer, 1998, 82(12):2334-2342.
[53] WANG S, XIONG H, YAN S, et al.Identification and Characterization of Epstein-Barr Virus Genomes in Lung Carcinoma Biopsy Samples by Next-Generation Sequencing Technology[J]. Sci Rep, 2016, 6:26156.
[54] JAFARIAN AH, OMIDI-ASHRAFI A, MOHAMADIAN-ROSHAN N, et al.Association of Epstein Barr virus deoxyribonucleic acid with lung carcinoma[J]. Indian J Pathol Microbiol, 2013, 56(4):359-364.
[55] BECNEL D, ABDELGHANI R, NANBO A, et al.Pathogenic Role of Epstein-Barr Virus in Lung Cancers[J]. Viruses, 2021, 13(5):877.
[56] 王宁, 李刚, 龚胜. 非小细胞肺癌合并HIV感染/AIDS手术患者病理和临床特征及术后并发症影响因素分析[J]. 新发传染病电子杂志, 2024, 9(2):29-33.
[57] BLAKE SJ, WOLF Y, BOURSI B, et al.Role of the microbiota in response to and recovery from cancer therapy[J]. Nat Rev Immunol, 2024, 24(5):308-325.
[58] PINATO DJ, HOWLETT S, OTTAVIANI D, et al.Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer[J]. JAMA Oncol, 2019, 5(12):1774-1778.
[59] JIN C, LAGOUDAS GK, ZHAO C, et al.Commensal Microbiota Promote Lung Cancer Development via γδ T Cells[J]. Cell, 2019, 176(5):998-1013.
[60] KABWE M, DASHPER S, BACHRACH G, et al. Bacteriophage manipulation of the microbiome associated with tumour microenvironments-can this improve cancer therapeutic response?[J]. FEMS Microbiol Rev, 2021, 45(5):fuab017.
[61] ZHANG M, ZHANG Y, SUN Y, et al.Intratumoral Microbiota Impacts the First-Line Treatment Efficacy and Survival in Non-Small Cell Lung Cancer Patients Free of Lung Infection[J]. J Healthc Eng, 2022, 2022:5466853.
[62] HILMI M, NEUZILLET C, LEFèVRE JH, et al. Prognostic Value of Fusobacterium nucleatum after Abdominoperineal Resection for Anal Squamous Cell Carcinoma[J]. Cancers (Basel), 2022, 14(7):1606.